A San Francisco-based biotechnology company that publicly launched today has acquired Portland-based TomegaVax Inc., an Oregon Health & Science University spinoff that is pursuing an HIV vaccine.
Vir Biotechnology is taking on “some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate,” the company’s announcement says. The company is "seeking to apply immune programming on an unprecedented scale."
“Vir is adopting a broad technological…
A San Francisco-based biotechnology company that publicly launched today has acquired Portland-based TomegaVax Inc., an Oregon Health & Science University spinoff that is pursuing an HIV vaccine.
Vir Biotechnology is taking on “some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate,” the company’s announcement says. The company is "seeking to apply immune programming on an unprecedented scale."
“Vir is adopting a broad technological…